Apnimed’s AD109 has the potential to be the first oral pharmaceutical drug that remedies both, the primary cause of OSA, nocturnal airway obstruction, and the daytime symptoms of OSA, such as fatigue.
The dual mode of action of AD109 leads to upper airway dilatation as well as enhanced breathing and oxygenation during sleep.
Results of the MARIPOSA Phase IIb trial, an efficacy, safety, and dose-finding study for AD109 support the advancement of the drug to Phase III.
If successful, AD109 could substantially alter the treatment of patients with varying disease intensities ranging from symptomatic snoring to more severe OSA.
Sleep disorders have becom...
